harvett, fair points.
We can only really go off what the company has said and it all restarted in August 2013 in this annc:
http://www.asx.com.au/asxpdf/20130820/pdf/42hshbts5rbpwj.pdf
and here's the manufacturing agreement annc:
http://www.asx.com.au/asxpdf/20131118/pdf/42kxv56rkpgv14.pdf
This proves they are at least doing what they say they are going to do.
AND
Aside from Oraline, they are are also looking at other acquisitions/transactions, hence this announcement:
http://www.asx.com.au/asxpdf/20131202/pdf/42lb5ds40vd6ks.pdf
And who knows, maybe others too?
So they are no longer a one-trick pony. I hold because there should be additional announcements along the way of Oralines path to commercialization, even if in the end they never make a $ from it, plus the two new directors became executive directors and are now seemingly working hard to make progress. See the announcements since their appointments. Unloved biotechs with a change of board and change of direction plus some cash for operations/acquisitions CAN result in massive value creation imo.
- Forums
- ASX - By Stock
- SBN
- small cap bio, massive potential only $4m m/c
small cap bio, massive potential only $4m m/c, page-16
-
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SBN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online